#ocrelizumab

[spooniestrong]

[currentsinbiology]

New Multiple Sclerosis Drug, Backed by 40 Years of Research, Could Halt Disease

A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS) – is holding new hope for the hundreds of thousands Americans living with the disease.

It also highlights the importance of clinician-scientists like UC San Francisco’s Stephen Hauser, MD, who are working to transform research into cures for patients.

The Food and Drug Administration on Tuesday approved ocrelizumab (brand name Ocrevus) to treat both relapsing-remitting MS and primary progressive MS, the first time a therapy has been available for severe forms of the disease.

The drug, the first that targets B cells in the human body, grew out of the work of Hauser, chair of neurology at UCSF, whose team persevered for decades in elucidating the science behind MS, defending findings that contradicted long-standing assumptions and translating the science into a therapy.

An MRI scan of a person with multiple sclerosis shows bright spots, which are MS plaques. NeuroscienceNews.com image is credited to NIH.

[merlinhoot]

[joseywritesng]

How does B cell therapy for multiple sclerosis work?

How does B cell therapy for multiple sclerosis work?

After Cherie Binn’s breakthrough symptoms of multiple sclerosis developed while being treated with an interferon drug, she weighed her options carefully. Finally, her neurologist prescribed rituximab. It’s a type of B cell therapy, which gets its name because it targets the B cells that cause nerve damage when you have MS. Binns, a 69-year-old nurse who works with MS patients in Wakefield, RI,…

View On WordPress

[sclerosismultiplex]

Kwalifikacje do leczenia okrelizumabem (Ocrevus)

[ultimavoce]

Sclerosi multipla: il nuovo farmaco somministrato su tre pazienti

Nuovi risultati per la #sclerosimultipla: il nuovo farmaco è stato testato su tre pazienti.

Ospedale Sant’Elia di Caltanissetta – Risale a qualche giorno fa il primo utilizzo dello Ocrelizumab; il nuovo farmaco è quasi in concomitanza con la giornata mondiale della sclerosi multipla.

Il farmaco è idoneo a forme primariamente progressive e secondariamente progressive, sino ad oggi intrattabili con farmaci specifici. Michele Vecchio, primario dell’ospedale di Sant’Elia e presidente…

View On WordPress

[meistrworld]

Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Blocking of a drug as a treatment for primary progressive multiple sclerosis (PPMS), making it unavailable for use by the UK’s National Health Service (NHS), is being challenged by the country’s MS Society.

And it has coupled its opposition with a call to arms – inviting everyone to #SpeakupforMS.

Holly (Pic: MS Society).

Holly, from the society’s campaigns community, lives with PPMS. She says:…

View On WordPress

[jsanruibal]

OCREVUS, el fármaco aprobado en la Unión Europea para el tratamiento de la esclerosis múltiple remitente-recurrente (EMRR) activa y la esclerosis múltiple primaria progresiva (EMPP)

Roche anunció que la Comisión Europea (CE) ha otorgado autorización de comercialización para OCREVUS (ocrelizumab) para pacientes con formas recurrentes activas de esclerosis múltiple definidas por características clínicas o de imagen y para pacientes con esclerosis múltiple primaria progresiva tempranaen términos de duración de la enfermedad y nivel de discapacidad, y con características de…

View On WordPress